騰盛博藥任命Coy Stout為高級副總裁、美國市場準入和患者權益倡導負責人
格隆匯9月28日丨Stout先生擁有超過25年的公共衞生和生物製藥行業領導者經驗，通過制定戰略商業計劃及構建基礎設施，他幫助美國患者快速獲得了各種疾病領域的重要藥物，特別是感染性疾病的治療藥物。
在加入騰盛博藥之前，Stout先生曾在吉利德科學公司，擔任美國商業及醫保準入副總裁，負責管理其的關鍵的美國業務。在其17年的吉利德任期內，他一直擔任重要的領導職位，包括負責商業及醫保準入，並與政府事務和政策團隊密切合作，為產品規劃舉措提供信息。除了在藥品覆蓋、創新支付模式和患者支持計劃等方面的經驗，Stout先生還曾在30多個產品的上市中領導了市場及醫保準入工作。作為患者關懷的倡導者，他還擁有社會工作者證書，曾在社區工作中負責團隊管理，致力於艾滋病患者的支持工作。
公司創始人及CEO 洪志博士對Stout的到來充滿期待“Stout在多種感染性疾病產品的市場準入和醫保策略方面擁有豐富的經驗。此外，他對公共衞生和患者關懷的熱情，將有助於我們建立一個成功的商業平台，將我們的COVID-19抗體療法提供給更多急需的患者。” Coy Stout對加入團隊表示：“騰盛博藥正處於令人興奮的發展期，我非常期待在這一時期加入公司，並利用我對行業的深入瞭解，以及我對醫療健康行業的熱情，最終為BRII-196/BRII-198和未來產品建立一個穩健的商業化計劃。”
由騰盛博藥Brii Bio (2137.HK) 參與研發的國產新冠中和抗體BRII-196/BRII-198“雞尾酒”療法日前發佈了好消息：國際三期臨牀試驗中期結果積極，體外嵌合病毒實驗檢測數據表明，此“雞尾酒”療法對所有已知變異株均保持中和活性。騰盛博藥Brii Bio (2137.HK)9月初宣佈追加1億美元，加碼該療法在全球註冊申請和商業化進程的“最後一公里”。此次Coy Stout的最新任命，或預示着該療法商業化的更進一步。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
